BiotechTube

CT-P55 + EU-approved Cosentyx

Phase 3Active
0 watching 0 views this week📈 Rising
77
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Plaque Psoriasis

Conditions

Plaque Psoriasis

Trial Timeline

May 26, 2025 → Oct 1, 2026

NCT ID
NCT06630559

About CT-P55 + EU-approved Cosentyx

CT-P55 + EU-approved Cosentyx is a phase 3 stage product being developed by Celltrion for Plaque Psoriasis. The current trial status is active. This product is registered under clinical trial identifier NCT06630559. Target conditions include Plaque Psoriasis.

Hype Score Breakdown

Clinical
27
Activity
18
Company
10
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT06630559Phase 3Active

Competing Products

20 competing products in Plaque Psoriasis

See all competitors
ProductCompanyStageHype Score
CT-P17 + EU-approved HumiraCelltrionPhase 3
77
alefacept + polyvalent pneumococcal vaccineAstellas PharmaApproved
85
alefaceptAstellas PharmaPhase 3
77
Amevive exposureAstellas PharmaPre-clinical
23
alefacept + placeboAstellas PharmaPhase 3
77
alefaceptAstellas PharmaApproved
85
alefaceptAstellas PharmaApproved
85
AlefaceptAstellas PharmaApproved
85
Halobetasol PropionateSun PharmaceuticalPhase 2
52
Placebo + SCD-044_Low Dose (Dose 1) + SCD-044_Intermediate Dose (Dose 2) + SCD-044_High Dose (Dose 3)Sun PharmaceuticalPhase 2
52
DSXS + PlaceboSun PharmaceuticalPhase 3
77
DSXSSun PharmaceuticalPhase 2
52
DSXS topicalSun PharmaceuticalPhase 2
52
Halobetasol Topical LotionSun PharmaceuticalApproved
85
Tildrakizumab 200 mg + Tildrakizumab 100 mg + Matching PlaceboSun PharmaceuticalPhase 3
77
DSXS1411 + PlaceboSun PharmaceuticalPhase 2
52
Tildrakizumab + PlaceboSun PharmaceuticalPhase 3
77
Tildrakizumab 200 mg + Tildrakizumab 100 mg + Tildrakizumab Placebo + Etanercept Placebo + Etanercept 50 mgSun PharmaceuticalPhase 3
77
MK-3222 200 mg + MK-3222 100 mg + Placebo to MK-3222 + Placebo to Etanercept + Etanercept 50 mgSun PharmaceuticalPhase 3
77
Topical TA-102 A + Topical TA-102 B + Topical TA-102 C + Topical TA-102 D + Topical TA-102 ESun PharmaceuticalPhase 1
33

Other Products from Celltrion

Azathioprine + PlaceboApproved
85
Infliximab CT-P13 + Immunosuppressors (Thiopurines or Methotrexate)Approved
85
Infliximab + Infliximab + InfliximabApproved
85
Pioglitazone + Alogliptin + Alogliptin + Metformin + DapagliflozinApproved
85
Pioglitazone 15 MG [Actos] + Empagliflozin 10 MG [Jardiance] + Empagliflozin 10 MG [Jardiance] + Pioglitazone 15 MG [Actos]Approved
85